HElping Alleviate the Longer-term consequences of COVID-19 (HEAL-COVID): national platform trial

This study, which will enrol patients admitted to hospital with Covid-19 who are about to be discharged, will investigate whether apixaban (for 2 weeks) or atorvastatin (for 12 months) could prevent or reduce long-term outcomes for patients with Covid-19.

Source:

HEAL-COVID